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1 Power analysis for the 2-year carcinogenicity study 
The main interest in the 2-year carcinogenicity study was whether the GM feeds resulted in a higher 
proportion of cancers as compared to the Control food, and whether there was an effect on survival.  
It is assumed that the rats develop cancers independently from each other, implying that there is no 
cage effect. Define 𝜋𝜋𝐶𝐶  as the probability that a Control rat develops a cancer and define 𝜋𝜋𝑇𝑇 as the 
probability that a rat fed with a GM feed develops a cancer. With 𝑁𝑁 Control rats, the number of rats 
that develop a cancer in the Control group follows a binomial distribution with binomial denominator 
𝑁𝑁 and probability 𝜋𝜋𝐶𝐶, and similarly for the GM group. It is of interest to know the power of a 
statistical test of the one-sided null hypotheses 𝐻𝐻0: 𝜋𝜋𝑇𝑇  ≤  𝜋𝜋𝐶𝐶  when 𝑁𝑁 rats are allotted to each group 
and when the true differences equals Δ = 𝜋𝜋𝑇𝑇 − 𝜋𝜋𝐶𝐶. Or, alternatively, given 𝜋𝜋𝐶𝐶  what value of 𝜋𝜋𝑇𝑇 can 
be found significantly different with a given power when testing with confidence level 𝛼𝛼. Here we will 
employ a power of 0.80, a confidence level 𝛼𝛼 = 0.05, and Fisher’s exact test which is the usual test 
when testing equality of binomial probabilities. Note that, due to the discrete nature of the data, the 
true confidence level of Fisher’s exact test will be smaller than 𝛼𝛼. Table 1 lists the values of 𝜋𝜋𝑇𝑇, for 
given values of 𝜋𝜋𝐶𝐶, that can be found significantly different with power 0.80 employing a one-sided 
Fisher’s exact test with confidence level 𝛼𝛼 = 0.05, for group size 𝑁𝑁 = 16, 50 and 100. These value of 𝑁𝑁 
are chosen because 16 is the amount of rats in the G-TwYST 90 days studies, 50 is the amount of rats 
used in the G-TwYST 2-year study, and 𝑁𝑁=100 was chose to see what happens when the number of 
rats is doubled. The values in Table 1 were obtained by means of the GenStat (VSN International, 
2015) simulation program in Appendix 1.  
Table 1 For given values of 𝝅𝝅𝑪𝑪 the minimal value of 𝝅𝝅𝑻𝑻 is given which can be found significantly 
different with power 0.80 when employing a one-sided Fisher exact test with 𝜶𝜶=0.05 for 
group sizes 𝑵𝑵 equal to 16, 50 and 100. 
𝜋𝜋𝐶𝐶  
𝜋𝜋𝑇𝑇 
𝑁𝑁 = 16 𝑁𝑁 = 50 𝑁𝑁 = 100 
0.001 0.39 0.13 0.07 
0.01 0.40 0.16 0.09 
0.05 0.46 0.23 0.16 
0.10 0.55 0.32 0.24 
0.20 0.67 0.45 0.37 
0.30 0.77 0.57 0.48 
0.40 0.86 0.67 0.58 
0.50 0.93 0.76 0.68 
0.60 0.99 0.84 0.77 
0.70 - 0.91 0.86 
0.80 - 0.97 0.93 
0.90 - - 0.99 
 
Table 1 reveals that with 𝑁𝑁=50 animals per group, or even with 𝑁𝑁=100 animals per group, only 
relatively large differences in probabilities will be found as significant with sufficient power. 
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Differences in survival rates between feeding groups in G-TwYST study A were assessed by means of 
Cox proportional hazard model. Sample size calculations for the comparison of survival curves 
between two groups under this model can be performed by means of the function ssizeCT.default() 
in the R package powerSurvEpi (Qiu et al, 2018). This function requires specification of the 
probabilities of death in both groups over the time period of the study, as well as the postulated 
hazard ratio. The observed probabilities of death at the end of the 2-year G-TwYST study A were 
between 0.5 and 0.7 for the different feeding groups. These observed probabilities were employed 
to obtain the hazard ratio which can be found significant with power 0.80 and significance level 0.05 
for group sizes of 𝑁𝑁 = 16, 50 and 100. The R program to calculate these is given in Appendix 2, and 
the resulting hazard ratios are given in Table 2. Note that this involves two-sided testing. The last 
column in Table 2 gives the minimum across the different probabilities, and is thus on the optimistic 
side.  
Table 2 Hazard ratio between a GM group and the Control group which can be found significant 
by two-sided testing with power 0.80 when employing a Cox proportional hazard model 
with 𝜶𝜶=0.05 for group sizes 𝑵𝑵 equal to 16, 50 and 100, and different values probabilities 
of death at the end of the study for Control (𝝅𝝅𝑪𝑪) and the GM group (𝝅𝝅𝑻𝑻). The last 
column gives the minimum hazard ratio for each row. 
𝜋𝜋𝐶𝐶  0.5 0.6 0.7 0.5 0.6 0.7 0.5 0.6 0.7 - 
𝜋𝜋𝑇𝑇 0.5 0.5 0.5 0.6 0.6 0.6 0.7 0.7 0.7 - 
𝑁𝑁 Hazard Ratio which can be found significant Minimum 
16 7.21 6.19 5.48 6.10 5.41 4.91 5.36 4.87 4.49 4.49 
50 2.43 2.32 2.23 2.31 2.23 2.15 2.22 2.15 2.08 2.08 
100 1.83 1.77 1.73 1.77 1.73 1.69 1.72 1.69 1.65 1.65 
 
 
Cox proportional hazard model does not fully specify a distribution for the time of death, but rather 
specifies a baseline hazard for the Control group and proportional hazards, or hazard ratios, for the 
GM groups. Alternatively a full distribution for the death times can be specified and it is customary to 
use the Weibull distribution for this, see e.g. https://en.wikipedia.org/wiki/Weibull_distribution. This 
distribution has two parameters: a scale parameter 𝜆𝜆 and a shape parameter 𝑘𝑘. Suppose that the 
death times of both the Control and the GM group follows a Weibull distribution with scale 
parameter 𝜆𝜆𝐶𝐶  and 𝜆𝜆𝑇𝑇 respectively and common shape parameter 𝑘𝑘. The ratio of the mean death 
times equals Δ = 𝜆𝜆𝑇𝑇 𝜆𝜆𝐶𝐶⁄  and we would like to know which value of Δ can be found significant with 
power 0.80 under a one-sided difference test of 𝐻𝐻0: 𝜆𝜆𝑇𝑇 ≤ 𝜆𝜆𝐶𝐶  with significance level 𝛼𝛼=0.05. This 
requires known values of 𝜆𝜆𝐶𝐶  and 𝑘𝑘, and also a known value for the group size 𝑁𝑁. Here we took values 
𝜆𝜆𝐶𝐶=2.141 and 𝑘𝑘=5.38 such that the median death time is 2 years and 90% of the control rats died 
before 2.5 years. The effect size Δ, which is significant with power 0.80,  was found by a GenStat 
(VSN International, 2015) simulation program which is given in Appendix 3. Note that the RSURVIVAL 
directive in GenStat employs the alternative parameterization given in Wikipedia. This implies that 
the null hypothesis is rejected for large, rather than small, values of the treatment effect. The 
resulting effect sizes with power 0.80 are given in Table 3 
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Table 3 The ratio 𝚫𝚫 of mean death times which can be found significant by one-sided testing 
with power 0.80 when employing a Weibull survival model with 𝜶𝜶=0.05 for group sizes 
𝑵𝑵 equal to 16, 50 and 100. The Weibull distribution for the Control feeding group is such 







2 Power analysis for the 90-days studies 
In G-TwYST studies A, B and C various endpoints were measured after 90 days. Based on the mean 
residual variance on the cage level across these three studies, for each endpoint the effect size is 
calculated which has power 0.80 when a two-sided test is employed with 𝛼𝛼=0.05. The design 
employed to calculate this effect size is a randomized block design with 5 feeds and 8 cages (or 
blocks) per feed, like in G-TwYST study B. This implies that the residual degrees of freedom equals 28. 
The mean residual standard errors for all endpoints are given in Appendix 4 for males and in 
Appendix 5 for females. The last column in these appendices, which is the squared root of the 
unweighted mean of the squared standard errors for the three studies, is used for the power 
analysis. The effect sizes are given in Table 4; they are calculated by means of the TPOWER 
procedure (Goedhart, 2016) in GenStat (VSN International, 2015). 
Table 4 Effect sizes as percentages plus and minus which can be found significant by two-sided 
testing with power 0.80 and confidence level 𝜶𝜶=0.05 for all continuous endpoints for 
males and females.  







Weights BodyWeight -7 7 -6 7 
Weights growthRate -3 3 -5 5 
Weights FeedMean -7 7 -8 9 







Haematology WBC -22 28 -24 32 
Haematology RBC -5 5 -6 6 
Haematology HGB -3 4 -4 4 
Haematology HCT -4 4 -5 5 
Haematology MCV -3 3 -3 3 
Haematology MCH -4 4 -4 4 
Haematology MCHC -2 2 -3 3 
Haematology PLT -18 21 -14 16 
Haematology LYMR -8 9 -9 9 
Haematology LYMA -23 29 -26 36 
G-TwYST power analysis  
4 
 







diffWBC Lymphocytes -10 11 -11 12 
diffWBC Neutrophils -21 27 -25 34 
diffWBC Monocytes -35 55 -42 72 
diffWBC Eosinophils -46 84 -66 198 







ClinChem ALP -19 24 -22 28 
ClinChem ALT -16 19 -23 30 
ClinChem AST -21 27 -22 29 
ClinChem BIL -24 32 -26 36 
ClinChem ALB -5 5 -8 9 
ClinChem TP -4 4 -6 6 
ClinChem Glu -15 17 -18 22 
ClinChem CHOL -13 15 -21 26 
ClinChem TAG -24 32 -24 32 
ClinChem Crea -14 16 -13 15 
ClinChem Urea -13 15 -14 16 
ClinChem cHGB -40 66 -37 60 
ClinChem Ca -2 2 -3 3 
ClinChem Cl -2 2 -2 2 
ClinChem K -9 10 -10 12 
ClinChem Na -1 1 -2 2 
ClinChem P -13 15 -20 25 







Urine uVol -34 51 -34 52 
Urine uVolW -34 52 -35 54 
Urine uLeu -49 96 -45 82 
Urine uOsmoll -31 45 -33 50 
Urine uKeton -67 203 -37 58 
Urine upH -35 54 -34 52 







Organs Kidney -9 10 -10 11 
Organs Spleen -12 14 -13 14 
Organs Liver -6 6 -9 9 
Organs AdrenGl -14 16 -12 14 
Organs Heart -7 8 -9 10 
Organs Thymus -17 20 -19 23 
Organs Testis/Uterus -9 10 -28 38 
Organs Epididymis/Ovary -11 12 -14 16 
Organs Brain -7 8 -7 8 
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Immunology Monocytes -10 11 -14 16 
Immunology Granulocytes -6 6 -7 7 
Immunology RespirBurst -12 13 -15 18 
Immunology Con -55 122 -56 125 
Immunology PHA -50 102 -56 125 
Immunology PWM -48 91 -49 97 
Immunology Medium -51 105 -43 75 
Immunology IprConA -37 60 -38 61 
Immunology IprPHA -38 60 -49 97 
Immunology IprPWM -33 48 -34 51 
Immunology G4c1 -62 161 -44 79 
Immunology G4c2 -68 211 -45 82 
Immunology G4c3 -65 186 -44 79 
Immunology NG2c1 -63 168 -43 76 
Immunology NG2c2 -69 220 -48 91 
Immunology NG2c3 -66 196 -45 83 
Immunology A6c1 -66 193 -41 70 
Immunology A6c2 -69 222 -45 82 
Immunology A6c3 -66 194 -46 86 
Immunology Med6d -72 261 -47 88 
Immunology IprG4c1 -41 69 -39 64 
Immunology IprG4c2 -31 44 -35 55 
Immunology IprG4c3 -40 67 -25 33 
Immunology IprNG2c1 -36 56 -34 51 
Immunology IprNG2c2 -33 49 -31 44 
Immunology IprNG2c3 -34 52 -27 36 
Immunology IprA6c1 -35 54 -24 32 
Immunology IprA6c2 -36 57 -25 34 
Immunology IprA6c3 -36 56 -30 43 







Cytokines IL2 -19 24 -18 23 
Cytokines IL4 -34 52 -48 93 
Cytokines IL10 -65 189 -71 240 
Cytokines IL17A -57 134 -33 50 
Cytokines TNFa -31 45 -26 34 
Cytokines IFNg -31 44 -43 74 







CellPhenotype sp3 -20 26 -15 18 
CellPhenotype sp3_4 -24 32 -18 22 
CellPhenotype sp3_8 -29 40 -17 20 
CellPhenotype sp3_45 -14 17 -11 12 
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CellPhenotype sp3_161 -16 20 -11 13 
CellPhenotype ln3 -18 22 -11 13 
CellPhenotype ln3_4 -19 24 -12 13 
CellPhenotype ln3_8 -19 23 -15 18 
CellPhenotype ln3_45 -24 32 -28 38 
CellPhenotype ty3 -18 22 -13 15 
CellPhenotype ty3_4 -17 20 -13 15 
CellPhenotype ty3_8 -20 25 -15 17 
CellPhenotype bm3 -43 77 -38 61 
CellPhenotype bm3_45 -10 11 -12 14 







Hormone Testosteron/betaEstr -43 77 -43 75 
Hormone T3 -12 14 -23 29 
Hormone T4 -11 12 -40 68 
 
A graphical display of the effect sizes for the main groups of endpoints, i.e. Weights, Haematology, 
diffWBC, CllinChem and Organs, are given in Figure 1 and Figure 2. Graphs for Urine and Immunology 
endpoints are given in Figure 3 and Figure 4, while graphs for Cytokines, CellPhenotype and Hormone 
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Figure 1 Effect sizes which can be found significant by two-sided testing with power 0.80 and 
confidence level 𝜶𝜶=0.05 for the main endpoints in males in a 90-days study. 





Figure 2 Effect sizes which can be found significant by two-sided testing with power 0.80 and 
confidence level 𝜶𝜶=0.05 for the main endpoints in females in a 90-days study. 




Figure 3 Effect sizes which can be found significant by two-sided testing with power 0.80 and 
confidence level 𝜶𝜶=0.05 for Urine/Immunology endpoints in males in a 90-days study. 




Figure 4 Effect sizes which can be found significant by two-sided testing with power 0.80 and 
confidence level 𝜶𝜶=0.05 for Urine/Immunology endpoints in females in a 90-days study. 




Figure 5 Effect sizes which can be found significant by two-sided testing with power 0.80 and 
𝜶𝜶=0.05 for Cytokines/CellPhenotype/Hormone endpoints in males in a 90-days study. 




Figure 6 Effect sizes which can be found significant by two-sided testing with power 0.80 and 
𝜶𝜶=0.05 for Cytokines/CellPhenotype/Hormone endpoints in females in a 90-days study. 
G-TwYST power analysis  
13 
 
Appendix 1. GenStat program for power of Fisher’s exact test 
" Define settings " 
scalar    alpha ; 0.05 
scalar    power ; 0.80 
scalar    seed  ; 39352 
scalar    ntimes ; 10000 
variate   NN ; !(16,50,100) 
variate   pControl ; !(0.1, 0.2 ... 0.9) 
" Prepare " 
calculate init = urand(seed ; 1) 
calculate nSample, nControl = nvalues(NN, pControl) 
variate   vpower ; !(#power) 
pointer   [suffixes=NN] pFit, pRaw 
variate   [nvalues=nControl] pFit[], pRaw[] ; deci=3 
for [ntimes=nSample ; index=iSample] 
  scalar    nbin, ntot ; (1,2) * NN$[iSample] 
  for [ntimes=nControl ; index=iControl] 
    " Simulate for Control group " 
    scalar    p0 ; pControl$[iControl] 
    calculate xControl = grbinomial(ntimes ; nbin ; p0) 
    " Simulate for list of values for Treatment group " 
    calculate p0plus = p0 + 0.005 
    variate   pTreat ; !(#p0, #p0plus ... 1) 
    calculate nTreat = nvalues(pTreat) 
    pointer   [nvalues=nTreat] xTreat, xSum, prob, pow 
    variate   [nvalues=nTreat] vpow ; deci=4 
    calculate xTreat[] = grbinomial(#nTreat(ntimes) ; nbin ; #pTreat) 
    " Do FisherExact and obtain power for each value of pTreat " 
    calculate xSum[] = xControl + xTreat[] 
    calculate prob[] = clhyper(#nTreat(xControl) ; xSum[] ; nbin ; ntot) 
    calculate pow[] = mean(prob[] .lt. alpha) 
    equate    pow ; vpow 
    " Fit smoothing spline to power values and interpolate " 
    subset    [vpow.le.0.9999] vpow, pTreat 
    model     [dist=binomial] vpow ; nbin=1 
    fit       [print=*] sspline(pTreat ; 4) 
    rkeep     fit=fit 
    interpola oldval=vpow,fit ; oldint=pTreat ; newval=vpower ; newint=p1,p2 
    calculate pFit[nbin]$[iControl] = p1 
    calculate pRaw[nbin]$[iControl] = p2 
  endfor 
endfor 
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Appendix 2. R program for power of Cox proportional hazard model 
# Define settings 
library(powerSurvEpi) 
alpha <- 0.05 
power <- 0.80 
ratio <- seq(from=1.1, to=10, by=0.01) 
pC <- rep(c(0.5, 0.6, 0.7), times=3) 
pT <- rep(c(0.5, 0.6, 0.7), each=3) 
NN <- c(16,50,100) 
# Prepare 
nRatio <- length(ratio) 
nProbs <- length(pT) 
result <- matrix(, nrow=length(NN), ncol=nProbs) 
rownames(result) <- NN 
# Calculate size in a loop by means of interpolation 
for (jj in 1:nProbs) { 
  ipT <- pT[jj] 
  ipC <- pC[jj] 
  size  <- NA*ratio 
  for (ii in 1:nRatio) { 
    size[ii] <- ssizeCT.default(power, ratio, ipT, ipC, ratio[ii], alpha)[1] 
  } 
  interpolate <- approx(size, ratio, NN)$y 
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Appendix 3. GenStat program for power of Weibull survival data 
" Define settings " 
scalar    seed   ; 3290128 
scalar    lambda ; 2.141 
scalar    kk     ; 5.38 
scalar    censor ; 2 
scalar    alpha  ; 0.05 
scalar    power  ; 0.80 
scalar    ntimes ; 1000 
variate   NN     ; !(16,50,100) ; deci=0 
variate   delta  ; !(1, 0.99...0.8) ; deci=2 
" Initialize " 
calculate init = urand(seed ; 1) 
variate   vpower ; !(#power) 
calculate nNN,ndelta = nvalues(NN,delta) 
" Loop over values " 
for [ntimes=nNN ; index=ii] 
  scalar    iNN ; NN$[ii] 
  variate   [nvalues=ndelta] powerTval ; deci=3 
  for [ntimes=ndelta ; index=jj] 
    scalar    idelta ; delta$[jj] 
    " Define structures to hold simulated samples " 
    factor    [nval=2*iNN*ntimes ; levels=2 ; values=#iNN(1,2)#ntimes] long 
    variate   [nvalues=2*iNN*ntimes] mu, weibull, cweibull 
    calculate mu = lambda * newlevels(long ; !(1, #idelta)) 
    pointer   [nvalues=ntimes] times, censored 
    variate   [nvalues=2*iNN] times[], censored[] 
    factor    [nvalues=2*iNN ; levels=2 ; values=#iNN(1,2)] treat 
    " Simulate by means of inversion of CDF; do censoring " 
    calculate weibull = mu * (-log(1-urand(0 ; 2*ntimes*iNN)))**(1/kk) 
    calculate cweibull = weibull.ge.censor 
    calculate weibull = bound(weibull ; 0 ; censor) 
    equate    weibull, cweibull ; times, censored 
    " Loop over ntimes datasets " 
    " The null hypotheses is rejected for large treatment effect " 
    variate   [nvalues=ntimes] esti,se 
    for [ntimes=ntimes ; index=idata] 
      rsurvival [print=* ; distribution=weibull ; times=times[idata] ; \ 
                censored=censored[idata]] treat 
      rkeep     esti=qesti ; se=qse 
      calculate (esti,se)$[idata] = (qesti,qse)$[2] 
    endfor 
    calculate pval = cunormal(esti/se) 
    calculate powerTval$[jj] = mean(pval.le.alpha) 
  endfor 
  " Interpolate to obtain effect size " 
  interpola oldval=powerTval ; oldint=delta ; newval=vpower ; newint=eff[ii] 
  print     iNN, eff[ii], delta, powerTval ; deci=0,3,2,3 
endfor 
print     NN, !(#eff) ; deci=0,2 
stop 
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Appendix 4. Residual standard errors for endpoints in males 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Weights BodyWeight 136 28 49 0.0484 0.0466 0.0512 0.0488 
Weights growthRate 136 28 49 0.0184 0.0224 0.0182 0.0198 
Weights FeedMean 136 28 49 0.0442 0.0486 0.0483 0.0471 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Haematology WBC 76 28 49 0.1739 0.1744 0.1656 0.1713 
Haematology RBC 76 28 49 0.0333 0.0440 0.0212 0.0341 
Haematology HGB 76 28 49 0.0271 0.0233 0.0222 0.0243 
Haematology HCT 76 28 49 0.0305 0.0349 0.0200 0.0292 
Haematology MCV 76 28 49 0.0251 0.0205 0.0162 0.0209 
Haematology MCH 76 28 49 0.0337 0.0281 0.0221 0.0284 
Haematology MCHC 76 28 49 0.0168 0.0190 0.0133 0.0165 
Haematology PLT 76 28 49 0.1280 0.1508 0.1210 0.1339 
Haematology LYMR 76 28 48 0.0659 0.0690 0.0365 0.0590 
Haematology LYMA 76 28 49 0.1836 0.1824 0.1606 0.1759 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
diffWBC Lymphocytes  28   0.0735  0.0735 
diffWBC Neutrophils  28   0.1632  0.1632 
diffWBC Monocytes  28   0.3019  0.3019 
diffWBC Eosinophils  28   0.4199  0.4199 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
ClinChem ALP 76 28 49 0.1570 0.1078 0.1740 0.1489 
ClinChem ALT 76 28 49 0.1083 0.1032 0.1503 0.1225 
ClinChem AST 76 28 49 0.1498 0.1371 0.1956 0.1628 
ClinChem BIL 76 28 49 0.2871 0.1164 0.1188 0.1915 
ClinChem ALB 76 28 49 0.0388 0.0274 0.0423 0.0367 
ClinChem TP 76 28 49 0.0308 0.0186 0.0229 0.0246 
ClinChem Glu 76 28 49 0.1076 0.1048 0.1146 0.1090 
ClinChem CHOL 76 28 49 0.0997 0.0965 0.0973 0.0978 
ClinChem TAG 76 28 49 0.1939 0.1773 0.1991 0.1903 
ClinChem Crea 76 28 49 0.1112 0.0771 0.1187 0.1039 
ClinChem Urea 76 28 49 0.0907 0.0860 0.1031 0.0935 
ClinChem cHGB 76 28 49 0.4139 0.2943 0.3296 0.3496 
ClinChem Ca 76 28 49 0.0201 0.0135 0.0145 0.0163 
ClinChem Cl 76 28 49 0.0150 0.0093 0.0147 0.0132 
ClinChem K 76 28 49 0.0754 0.0451 0.0707 0.0651 
ClinChem Na 75 28 49 0.0090 0.0079 0.0101 0.0090 
ClinChem P 76 28 49 0.0817 0.0895 0.1142 0.0961 
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Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Urine uVol 36 28 49 0.2715 0.2960 0.2888 0.2856 
Urine uVolW 36 28 49 0.2840 0.2977 0.2827 0.2882 
Urine uLeu 36 28 49 0.3940 0.5672 0.4098 0.4636 
Urine uOsmoll 36 28 49 0.2783 0.2396 0.2526 0.2573 
Urine uKeton 36 28 49 0.6068 1.0358 0.5557 0.7637 
Urine upH 36 28 49 0.2973 0.2428 0.3412 0.2965 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Organs Kidney  28 49  0.0727 0.0637 0.0683 
Organs Spleen  28 49  0.0824 0.0930 0.0879 
Organs Liver  28 49  0.0407 0.0386 0.0397 
Organs AdrenGl  28 49  0.1012 0.1032 0.1022 
Organs Heart  28 49  0.0519 0.0551 0.0535 
Organs Thymus  28 49  0.1177 0.1310 0.1245 
Organs Testis  28 49  0.0657 0.0632 0.0644 
Organs Epididymis  28 49  0.0766 0.0769 0.0768 
Organs Brain  28 49  0.0507 0.0518 0.0513 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Immunology Monocytes   31   0.0746 0.0746 
Immunology Granulocytes  16 31  0.0441 0.0402 0.0422 
Immunology RespirBurst  16 31  0.1055 0.0635 0.0871 
Immunology Con  16 31  0.3553 0.6907 0.5492 
Immunology PHA  16 31  0.2943 0.6165 0.4831 
Immunology PWM  16 31  0.4142 0.4754 0.4458 
Immunology Medium  16 31  0.3444 0.6080 0.4941 
Immunology IprConA  16 31  0.3515 0.2894 0.3220 
Immunology IprPHA  16 31  0.2931 0.3531 0.3245 
Immunology IprPWM  16 31  0.2261 0.3116 0.2722 
Immunology G4c1   31   0.6598 0.6598 
Immunology G4c2   31   0.7819 0.7819 
Immunology G4c3   31   0.7240 0.7240 
Immunology NG2c1   31   0.6797 0.6797 
Immunology NG2c2   31   0.8025 0.8025 
Immunology NG2c3   31   0.7483 0.7483 
Immunology A6c1   31   0.7419 0.7419 
Immunology A6c2   31   0.8059 0.8059 
Immunology A6c3   31   0.7437 0.7437 
Immunology Med6d   31   0.8854 0.8854 
Immunology IprG4c1   31   0.3604 0.3604 
Immunology IprG4c2   31   0.2524 0.2524 
Immunology IprG4c3   31   0.3537 0.3537 
Immunology IprNG2c1   31   0.3059 0.3059 
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Immunology IprNG2c2   31   0.2727 0.2727 
Immunology IprNG2c3   31   0.2881 0.2881 
Immunology IprA6c1   31   0.2970 0.2970 
Immunology IprA6c2   31   0.3117 0.3117 
Immunology IprA6c3   31   0.3047 0.3047 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Cytokines IL2  16   0.1494  0.1494 
Cytokines IL4  16   0.2899  0.2899 
Cytokines IL10  16   0.7303  0.7303 
Cytokines IL17A  16   0.5854  0.5854 
Cytokines TNFa  16   0.2538  0.2538 
Cytokines IFNg  16   0.2511  0.2511 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
CellPhenotype sp3  16 31  0.1215 0.1872 0.1578 
CellPhenotype sp3_4  16 31  0.1292 0.2390 0.1921 
CellPhenotype sp3_8  16 31  0.1360 0.2996 0.2326 
CellPhenotype sp3_45  15 31  0.0386 0.1453 0.1063 
CellPhenotype sp3_161  15 31  0.0647 0.1619 0.1233 
CellPhenotype ln3  16 31  0.1377 0.1312 0.1345 
CellPhenotype ln3_4  16 31  0.1605 0.1331 0.1475 
CellPhenotype ln3_8  16 31  0.1209 0.1591 0.1413 
CellPhenotype ln3_45  16 30  0.1463 0.2313 0.1935 
CellPhenotype ty3  16 31  0.1289 0.1487 0.1392 
CellPhenotype ty3_4  16 31  0.1219 0.1328 0.1275 
CellPhenotype ty3_8  16 31  0.1362 0.1740 0.1563 
CellPhenotype bm3   31   0.3917 0.3917 
CellPhenotype bm3_45   31   0.0733 0.0733 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Hormone Testosteron  20   0.3923  0.3923 
Hormone T3  20   0.0891  0.0891 
Hormone T4  20   0.0766  0.0766 
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Appendix 5. Residual standard errors for endpoints in females 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Weights BodyWeight 136 28 49 0.048 0.047 0.051 0.049 
Weights growthRate 136 28 49 0.018 0.022 0.018 0.020 
Weights FeedMean 136 28 49 0.044 0.049 0.048 0.047 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Haematology WBC 76 28 49 0.174 0.174 0.166 0.171 
Haematology RBC 76 28 49 0.033 0.044 0.021 0.034 
Haematology HGB 76 28 49 0.027 0.023 0.022 0.024 
Haematology HCT 76 28 49 0.031 0.035 0.020 0.029 
Haematology MCV 76 28 49 0.025 0.020 0.016 0.021 
Haematology MCH 76 28 49 0.034 0.028 0.022 0.028 
Haematology MCHC 76 28 49 0.017 0.019 0.013 0.017 
Haematology PLT 76 28 49 0.128 0.151 0.121 0.134 
Haematology LYMR 76 28 48 0.066 0.069 0.036 0.059 
Haematology LYMA 76 28 49 0.184 0.182 0.161 0.176 





























Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
ClinChem ALP 76 28 49 0.157 0.108 0.174 0.149 
ClinChem ALT 76 28 49 0.108 0.103 0.150 0.122 
ClinChem AST 76 28 49 0.150 0.137 0.196 0.163 
ClinChem BIL 76 28 49 0.287 0.116 0.119 0.192 
ClinChem ALB 76 28 49 0.039 0.027 0.042 0.037 
ClinChem TP 76 28 49 0.031 0.019 0.023 0.025 
ClinChem Glu 76 28 49 0.108 0.105 0.115 0.109 
ClinChem CHOL 76 28 49 0.100 0.096 0.097 0.098 
ClinChem TAG 76 28 49 0.194 0.177 0.199 0.190 
ClinChem Crea 76 28 49 0.111 0.077 0.119 0.104 
ClinChem Urea 76 28 49 0.091 0.086 0.103 0.094 
ClinChem cHGB 76 28 49 0.414 0.294 0.330 0.350 
ClinChem Ca 76 28 49 0.020 0.013 0.014 0.016 
ClinChem Cl 76 28 49 0.015 0.009 0.015 0.013 
ClinChem K 76 28 49 0.075 0.045 0.071 0.065 
ClinChem Na 75 28 49 0.009 0.008 0.010 0.009 
ClinChem P 76 28 49 0.082 0.090 0.114 0.096 
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Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Urine uVol 36 28 49 0.272 0.296 0.289 0.286 
Urine uVolW 36 28 49 0.284 0.298 0.283 0.288 
Urine uLeu 36 28 49 0.394 0.567 0.410 0.464 
Urine uOsmoll 36 28 49 0.278 0.240 0.253 0.257 
Urine uKeton 36 28 49 0.607 1.036 0.556 0.764 
Urine upH 36 28 49 0.297 0.243 0.341 0.296 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Organs Kidney  28 49  0.073 0.064 0.068 
Organs Spleen  28 49  0.082 0.093 0.088 
Organs Liver  28 49  0.041 0.039 0.040 
Organs AdrenGl  28 49  0.101 0.103 0.102 
Organs Heart  28 49  0.052 0.055 0.054 
Organs Thymus  28 49  0.118 0.131 0.125 
Organs Uterus  28 49  0.066 0.063 0.064 
Organs Ovary  28 49  0.077 0.077 0.077 
Organs Brain  28 49  0.051 0.052 0.051 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Immunology Monocytes   31   0.075 0.075 
Immunology Granulocytes  16 31  0.044 0.040 0.042 
Immunology RespirBurst  16 31  0.105 0.064 0.087 
Immunology Con  16 31  0.355 0.691 0.549 
Immunology PHA  16 31  0.294 0.616 0.483 
Immunology PWM  16 31  0.414 0.475 0.446 
Immunology Medium  16 31  0.344 0.608 0.494 
Immunology IprConA  16 31  0.351 0.289 0.322 
Immunology IprPHA  16 31  0.293 0.353 0.325 
Immunology IprPWM  16 31  0.226 0.312 0.272 
Immunology G4c1   31   0.660 0.660 
Immunology G4c2   31   0.782 0.782 
Immunology G4c3   31   0.724 0.724 
Immunology NG2c1   31   0.680 0.680 
Immunology NG2c2   31   0.803 0.803 
Immunology NG2c3   31   0.748 0.748 
Immunology A6c1   31   0.742 0.742 
Immunology A6c2   31   0.806 0.806 
Immunology A6c3   31   0.744 0.744 
Immunology Med6d   31   0.885 0.885 
Immunology IprG4c1   31   0.360 0.360 
Immunology IprG4c2   31   0.252 0.252 
Immunology IprG4c3   31   0.354 0.354 
Immunology IprNG2c1   31   0.306 0.306 
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Immunology IprNG2c2   31   0.273 0.273 
Immunology IprNG2c3   31   0.288 0.288 
Immunology IprA6c1   31   0.297 0.297 
Immunology IprA6c2   31   0.312 0.312 
Immunology IprA6c3   31   0.305 0.305 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Cytokines IL2  16   0.149  0.149 
Cytokines IL4  16   0.290  0.290 
Cytokines IL10  16   0.730  0.730 
Cytokines IL17A  16   0.585  0.585 
Cytokines TNFa  16   0.254  0.254 
Cytokines IFNg  16   0.251  0.251 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
CellPhenotype sp3  16 31  0.122 0.187 0.158 
CellPhenotype sp3_4  16 31  0.129 0.239 0.192 
CellPhenotype sp3_8  16 31  0.136 0.300 0.233 
CellPhenotype sp3_45  15 31  0.039 0.145 0.106 
CellPhenotype sp3_161  15 31  0.065 0.162 0.123 
CellPhenotype ln3  16 31  0.138 0.131 0.135 
CellPhenotype ln3_4  16 31  0.161 0.133 0.147 
CellPhenotype ln3_8  16 31  0.121 0.159 0.141 
CellPhenotype ln3_45  16 30  0.146 0.231 0.194 
CellPhenotype ty3  16 31  0.129 0.149 0.139 
CellPhenotype ty3_4  16 31  0.122 0.133 0.127 
CellPhenotype ty3_8  16 31  0.136 0.174 0.156 
CellPhenotype bm3   31   0.392 0.392 
CellPhenotype bm3_45   31   0.073 0.073 
Group Endpoint dfResA dfResB dfResC seResA seResB seResC seRes 
Hormone Testosteron  20   0.392  0.392 
Hormone T3  20   0.089  0.089 
Hormone T4  20   0.077  0.077 
 
